Trials / Recruiting
RecruitingNCT05387369
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
Detailed description
The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paxlovid | The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected. |
Timeline
- Start date
- 2022-03-21
- Primary completion
- 2023-03-30
- Completion
- 2027-03-30
- First posted
- 2022-05-24
- Last updated
- 2022-05-24
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05387369. Inclusion in this directory is not an endorsement.